These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7594346)

  • 21. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
    Murakami M; Saita H; Takahashi Y; Kusaka S; Asagoe K; Dekigai H; Matsumoto M; Seki M; Mizuno M; Maeda S
    J Clin Gastroenterol; 1995; 20 Suppl 2():S79-82. PubMed ID: 7594348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence.
    Parente F; Bargiggia S; Bollani S; Colombo E; Bianchi Porro G
    Hepatogastroenterology; 1998; 45(22):990-3. PubMed ID: 9755995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
    Shimoyama T; Munakata A; Mizuki I; Akagi T; Fukuda S; Ohkawa K; Yoshida Y; Aisawa T; Sakata Y; Fukushi M
    J Clin Gastroenterol; 1995; 20 Suppl 2():S125-7. PubMed ID: 7594328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of lansoprazole in eradication of Helicobacter pylori.
    Takimoto T; Ido K; Taniguchi Y; Satoh K; Saifuku K; Kihira K; Yoshida Y; Kimura K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S121-4. PubMed ID: 7594327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Usefulness of every-other day administration of proton pump inhibitors from the standpoint of continuous 48-hour pH measurements-- Comparison of cimetidine, omeprazole, and lansoprazole].
    Yamamoto Y; Sezai S; Sakurabayashi S; Hirano M; Oka H
    Nihon Shokakibyo Gakkai Zasshi; 1995 Jun; 92(6):919-24. PubMed ID: 7609313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group.
    Avner DL; Dorsch ER; Jennings DE; Greski-Rose PA
    Aliment Pharmacol Ther; 1995 Oct; 9(5):521-8. PubMed ID: 8580272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
    Asaki S; Sato A; Sakurada H; Takeda T; Hongo M; Toyota T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S56-8. PubMed ID: 7594342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
    Kromer W; Horbach S; Lühmann R
    Pharmacology; 1999 Aug; 59(2):57-77. PubMed ID: 10450061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.
    Lanza F; Goff J; Silvers D; Winters J; Jhala N; Jennings D; Greski-Rose P
    Dig Dis Sci; 1997 Dec; 42(12):2529-36. PubMed ID: 9440632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical study on the pathophysiology and treatment of PPI-resistant ulcers.
    Ashida K; Sakaguchi M; Tanaka M; Takiuchi H; Egashira Y; Katsu K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S67-71. PubMed ID: 7594345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Eradication effect of lansoprazole-based triple therapy against H. pylori].
    Sugiyama T; Asaka M
    Nihon Rinsho; 2004 Mar; 62(3):483-8. PubMed ID: 15038091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.
    Graham DY; Agrawal NM; Campbell DR; Haber MM; Collis C; Lukasik NL; Huang B;
    Arch Intern Med; 2002 Jan; 162(2):169-75. PubMed ID: 11802750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An extensive metabolizer with recurrent ulcer responding to high dose of lansoprazole.
    Higuchi K; Tanabe S; Koizumi W; Nakayama N; Sasaki T; Nagaba S; Saigenji K; Katada N
    Hepatogastroenterology; 2004; 51(57):774-6. PubMed ID: 15143914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A trial of lansoprazole in refractory gastric ulcer.
    van Rensburg CJ; Louw JA; Girdwood AH; Simjee AE; Marks IN
    Aliment Pharmacol Ther; 1996 Jun; 10(3):381-6. PubMed ID: 8791967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.